# RPS6KA1 Remodels Fatty Acid Metabolism and Suppresses Malignant Progression in Colorectal Cancer

## TL;DR

This study identifies RPS6KA1 as a key gene that suppresses colorectal cancer by regulating fatty acid metabolism and improving immune response.

## Contribution

The study reveals RPS6KA1 as a novel tumor-suppressive gene linked to fatty acid metabolism in colorectal cancer.

## Key findings

- RPS6KA1 is significantly downregulated in colorectal cancer and associated with poor prognosis.
- RPS6KA1 modulates fatty acid metabolism and inhibits cancer progression in cellular and animal models.
- RPS6KA1 enhances antitumor immune functions of CD8+T and follicular helper T cells.

## Abstract

Background: Colorectal cancer (CRC), with high incidence but low rates of early diagnosis, poses significant challenges to public health worldwide. Lipid metabolic reprogramming has been closely associated with CRC occurrence and development. This study aimed to identify key fatty acid metabolism-related molecules involved in the development of CRC and to explore potential prognostic biomarkers and therapeutic targets. Methods: Based on The Cancer Genome Atlas (TCGA) data from colon adenocarcinoma (COAD) patients, we applied weighted gene co-expression network analysis (WGCNA), Cox regression, and least absolute shrinkage and selection operator (LASSO) to identify fatty acid metabolism-related signature genes in CRC. Expression validation and prognostic analysis were conducted. Summary-data-based Mendelian randomization (SMR) was used to infer causal relationships between target genes and CRC. Single-cell transcriptomics and immune infiltration analysis elucidated underlying pathogenic mechanisms. Cellular and animal experiments validated tumor-suppressive effects and lipid metabolic regulatory mechanisms. Results: RPS6KA1 and CHGA were identified as fatty acid metabolism-related signature genes in COAD. Only RPS6KA1 was significantly downregulated in COAD and negatively correlated with poor prognosis (p = 0.0069). SMR confirmed its tumor-suppressive role, potentially associated with enhanced antitumor functions of CD8+T cells and follicular helper T cells. In vitro and in vivo experiments demonstrated that RPS6KA1 inhibits malignant progression of colon cancer and modulates fatty acid metabolism. Conclusions: Integrated multi-dimensional bioinformatic and experimental analyses reveal that RPS6KA1 remodels fatty acid metabolism and suppresses malignant progression, indicating its value as a prognostic biomarker in CRC and providing new insights for therapeutic strategies.